Syros Pharmaceuticals, Inc. (SYRS)
NASDAQ: SYRS · IEX Real-Time Price · USD
6.27
+0.21 (3.47%)
Jul 19, 2024, 12:00 AM EDT - Market open
Syros Pharmaceuticals Employees
Syros Pharmaceuticals had 68 employees as of December 31, 2023. The number of employees decreased by 49 or -41.88% compared to the previous year.
Employees
68
Change (1Y)
-49
Growth (1Y)
-41.88%
Revenue / Employee
$102,662
Profits / Employee
-$2,124,897
Market Cap
167.59M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
TruBridge | 3,219 |
OrganiGram Holdings | 984 |
Repare Therapeutics | 179 |
Rigel Pharmaceuticals | 147 |
Stereotaxis | 122 |
Adverum Biotechnologies | 121 |
Compugen | 68 |
Acumen Pharmaceuticals | 52 |
SYRS News
- 5 weeks ago - Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression - Business Wire
- 2 months ago - Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update - Business Wire
- 2 months ago - Syros to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024 - Business Wire
- 3 months ago - Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression - Business Wire
- 3 months ago - Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 3 months ago - Top 3 Health Care Stocks You'll Regret Missing This Month - Humana (NYSE:HUM), Disc Medicine (NASDAQ:IRON) - Benzinga
- 4 months ago - Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update - Business Wire